Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

 

 

Main Contacts  Pro EuroDILINet

General enquiries: info@proeurodilinet.eu


Dr Raul ANDRADE
Chair

Prof Guruprasad AITHAL
Vice Chair

Dr Rossella MAGLI
Science officer

Ms Nathalie WARENGHIEN
Administrative officer

Prof. Gerd A Kullak Ublick.

Prof. Gerd A Kullak Ublick.

WORKING GROUP 2. DILI RISK STRATIFICATION

Leader (gerd.kullak@usz.ch)

University Hospital Zurich (Switzerland)

 

  • Professor of Clinical Pharmacology and Toxicology, Director of the Department of Clinical Pharmacology and Toxicology, University Hospital Zurich
  • Head of the regional pharmacovigilance centre at the University Hospital Zurich
  • Global Head of Mechanistic Safety and Chair of the Hepatic Safety Team, Novartis Global Drug Development
  • Work package lead of the DILI work package in the IMI SAFE-T consortium and the IMI TransBioLine consortium
  • The risk of DILI is strongly dependent on the drug administered and on host factors that determine the individual response. Risk stratification should focus on the following:
    • Characterization of the risk profile and mechanism of toxicity of newer hepatotoxic agents, e.g. tyrosine kinase inhibitors or immune checkpoint inhibitors
    • Evaluation of novel biomarkers for DILI for the prediction of severe DILI in patients
    • Investigation of individual susceptibility factors that anticípate a risk for DILI